Format

Send to

Choose Destination
Nat Rev Clin Oncol. 2009 Jun;6(6):306-7. doi: 10.1038/nrclinonc.2009.69.

Genetics: Predictive value of KRAS mutations in chemoresistant CRC.

Author information

1
INSERM Laboratory, Paris, France.

Abstract

On the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.

PMID:
19483733
DOI:
10.1038/nrclinonc.2009.69
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center